Q fever primary prevention: Difference between revisions
Jump to navigation
Jump to search
Ahmed Younes (talk | contribs) No edit summary |
Ahmed Younes (talk | contribs) No edit summary |
||
| Line 27: | Line 27: | ||
===Q fever vaccine=== | ===Q fever vaccine=== | ||
*An intradermal vaccine composed of killed ''Coxiella burnetii'' organisms has been developed and has successfully protected humans in occupational settings in Australia. However, this vaccine is not commercially available in the United States. | *An intradermal vaccine composed of killed ''Coxiella burnetii'' organisms has been developed and has successfully protected humans in occupational settings in Australia. However, this vaccine is not commercially available in the United States.<ref name="pmid8202006">{{cite journal |vauthors=Ackland JR, Worswick DA, Marmion BP |title=Vaccine prophylaxis of Q fever. A follow-up study of the efficacy of Q-Vax (CSL) 1985-1990 |journal=Med. J. Aust. |volume=160 |issue=11 |pages=704–8 |year=1994 |pmid=8202006 |doi= |url=}}</ref> | ||
*In 2001, Australia introduced a national Q fever vaccination program for people working in "at risk" occupations. | *In 2001, Australia introduced a national Q fever vaccination program for people working in "at risk" occupations. | ||
*Persons wishing to be vaccinated should first have a skin and blood test to determine a history of previous exposure. Individuals who have previously been exposed to ''C. burnetii'' should not receive the vaccine because severe reactions localized to the area of the injected vaccine may occur. | *Persons wishing to be vaccinated should first have a skin and blood test to determine a history of previous exposure. Individuals who have previously been exposed to ''C. burnetii'' should not receive the vaccine because severe reactions localized to the area of the injected vaccine may occur. | ||
*After a single dose of vaccine, protective immunity lasts for many years and revaccination is not generally required. | *After a single dose of vaccine, protective immunity lasts for many years and revaccination is not generally required. | ||
*A vaccine for use in animals has also been developed, but it is not available in the United States. | *A vaccine for use in animals has also been developed, but it is not available in the United States.<ref name="urlClinical aspects and prevention of Q fever in animals | SpringerLink">{{cite web |url=https://link.springer.com/article/10.1007/BF00140132 |title=Clinical aspects and prevention of Q fever in animals | SpringerLink |format= |work= |accessdate=}}</ref> | ||
==References== | ==References== | ||
Revision as of 18:35, 9 June 2017
|
Q fever Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Q fever primary prevention On the Web |
|
American Roentgen Ray Society Images of Q fever primary prevention |
|
Risk calculators and risk factors for Q fever primary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Ahmed Younes M.B.B.CH [2]
Overview
Effective measures for the primary prevention of Q fever include educating the public on sources of infection, appropriate disposal of placenta, birth products, fetal membranes, and aborted fetuses at facilities housing sheep and goats and restricting access to barns and laboratories used in housing potentially infected animals.
Prevention
 |
In the United States, Q fever outbreaks have resulted mainly from occupational exposure involving veterinarians, meat processing plant workers, sheep and dairy workers, livestock farmers, and researchers at facilities housing sheep. Prevention and control efforts should be directed primarily toward these groups and environments.
The following measures should be used in the prevention and control of Q fever:[1]
- Educate the public on sources of infection.
- Appropriately dispose of placenta, birth products, fetal membranes, and aborted fetuses at facilities housing sheep and goats.
- Restrict access to barns and laboratories used in housing potentially infected animals.
- Use only pasteurized milk and milk products.
- Use appropriate procedures for bagging, autoclaving, and washing of laboratory clothing.
- Vaccinate (where possible) individuals engaged in research with pregnant sheep or live C. burnetii.
- Quarantine imported animals.
- Ensure that holding facilities for sheep should be located away from populated areas. Animals should be routinely tested for antibodies to C. burnetii, and measures should be implemented to prevent airflow to other occupied areas.
- Counsel persons at highest risk for developing chronic Q fever, especially persons with pre-existing cardiac valvular disease or individuals with vascular grafts.
Q fever vaccine
- An intradermal vaccine composed of killed Coxiella burnetii organisms has been developed and has successfully protected humans in occupational settings in Australia. However, this vaccine is not commercially available in the United States.[2]
- In 2001, Australia introduced a national Q fever vaccination program for people working in "at risk" occupations.
- Persons wishing to be vaccinated should first have a skin and blood test to determine a history of previous exposure. Individuals who have previously been exposed to C. burnetii should not receive the vaccine because severe reactions localized to the area of the injected vaccine may occur.
- After a single dose of vaccine, protective immunity lasts for many years and revaccination is not generally required.
- A vaccine for use in animals has also been developed, but it is not available in the United States.[3]
References
- ↑ Fenollar F, Fournier PE, Carrieri MP, Habib G, Messana T, Raoult D (2001). "Risks factors and prevention of Q fever endocarditis". Clin. Infect. Dis. 33 (3): 312–6. doi:10.1086/321889. PMID 11438895.
- ↑ Ackland JR, Worswick DA, Marmion BP (1994). "Vaccine prophylaxis of Q fever. A follow-up study of the efficacy of Q-Vax (CSL) 1985-1990". Med. J. Aust. 160 (11): 704–8. PMID 8202006.
- ↑ "Clinical aspects and prevention of Q fever in animals | SpringerLink".